Thus, the striking disease-specific cooverexpression of TET3 and VHL would likely increase the specificity of Bc action and explain, at least in part, the high efficacy and low toxicity of Bc in our mouse endometriosis therapy studies (Figure 7 and Supplemental Figures 16 and 17). The gene discussed is VHL; the disease is endometriosis.